Notícias e Atividades da Serb Pharmaceuticals

Serb Pharmaceuticals tem presença direta em 2 países.

Eles estão dentro:

• Farmacêutica50%
• Biotecnologia50%

Fusão, aquisição e financiamento envolvendo Serb Pharmaceuticals.

• Serb Pharmaceuticals adquiriu Y-mAbs Therapeutics (publicado em 17 de setembro de 2025).
• Serb Pharmaceuticals has announced the acquisition of Y-mAbs Therapeutics  (publicado em 6 de agosto de 2025).

Veja o organograma con seus 35 executivos principais

Biografias mais buscadas da Serb Pharmaceuticals

• Vanessa Wolfeler, Chief Executive Officer
• Jeremie Urbain, Chairman of the Board
• Arthur Pignot, Chief Strategy Officer

Recentes movimentos de executivos em Serb Pharmaceuticals

• Cecile Baradez, ingressou na Companhia como Medical Science Liaisons Director  (Notícia publicada em 11 de maio de 2026).
• Neha Chawla antes Senior Director, Commercial Operations, foi promovido a Executive Director, Commercial Operations  (Notícia publicada em 24 de março de 2026).

Criar um alerta
para seguir os movimentos de executivos da Serb Pharmaceuticals.

Serb Pharmaceuticals possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Serb Pharmaceuticals

• SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million - SERB Pharmaceuticals
• SERB Pharmaceuticals Announces ThyroSafe 130mg Potassium Iodide Tablets are Now Commercially Available in the US - SERB Pharmaceuticals
• Y-mAbs Announces Publication in Cancers - SERB Pharmaceuticals
• SERB Pharmaceuticals Expands Scientific Leadership with Appointment of Dr. Peter C. Adamson to US Board  - SERB Pharmaceuticals
• Dr. Vignesh Rajah Appointed as SERB Pharmaceuticals’ Chief Medical Officer - SERB Pharmaceuticals
• SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics - SERB Pharmaceuticals
• SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics - SERB Pharmaceuticals
• SFJ Pharmaceuticals and SERB Pharmaceuticals Present Positive Final Results from Pivotal Phase 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding  - SERB Ph
• Newly published study shows that Voraxaze® can improve clinical outcomes in patients with high-dose methotrexate induced acute kidney injury - SERB Pharmaceuticals
• First FDA-approved treatment for severe frostbite now commercially available in the US  - SERB Pharmaceuticals
• View more press releases Close

Redes sociais sobre Serb Pharmaceuticals

• Serb Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Serb Pharmaceuticals na LinkedIn, X (Twitter) e YouTube